The endTB project is led by Médecins Sans Frontières/Doctors Without Borders (MSF), Partners In Health (PIH) and Interactive Research and Development. Main funder is Unitaid. endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through access to new drugs, two clinical trials, advocacy at national and global levels.

These pictures were taken on one of the endTB-Q trial sites. endTB-Q is a clinical trial that seeks to radically improve treatment for a strain of TB that is resistant to the most important standard medications, known as pre-extensively resistant (pre-XDR) TB. endTB-Q is a phase III, randomised, controlled and open-label clinical trial that began in 2020. More than 300 patients from six countries – India, Kazakhstan, Lesotho, Pakistan, Peru and Vietnam – have now enrolled in the trial. It assesses the safety and efficacy of a combination of newly approved TB drugs (bedaquiline and delamanid) with drugs previously used for other diseases (clofazimine and linezolid) for the treatment of pre-XDR TB.